Showing 3351-3360 of 3598 results for "".
- Congrats: Dr. Barbara Gilchrest Receives the 24th David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-barbara-gilchrest-receives-the-24th-david-martin-carter-mentor-award/2458556/Barbara A. Gilchrest, MD of Harvard Medical School and Massachusetts General Hospital in Boston received the David Martin Carter Mentor Award at the Annual Meeting of the Society for Investigative Dermatology in Scottsdale, Ariz. Dr. Gilchrest plus the recipients of The Researc
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Galderma Unveils the New Cetaphil Brand Graphics & Packaginghttps://practicaldermatology.com/news/galderma-unveils-the-new-cetaphil-brand-graphics-packaging/2458590/Galderma Laboratories, L.P., redesigned the graphics and packaging of its Cetaphil product line to provide a more simplified shopping experience at shelf, improved portfolio differentiation, as well as clarity of product benefits. "The packaging
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- New MRF White Paper Provides Road Map for Eradicating Melanomahttps://practicaldermatology.com/news/new-mrf-white-paper-provides-road-map-for-eradicating-melanoma/2458604/More research needs to be done about what range of wavelengths in the ultraviolet band need to be blocked to prevent melanoma, according to a new white paper from Melanoma Research Foundation (MRF). The paper, "The Stat
- Study on TRASER for Nasal Spider Veins Scores Top Honors from ASLMShttps://practicaldermatology.com/news/study-on-traser-for-nasal-spider-veins-scores-top-honors-from-aslms/2458606/Houston dermatologist Paul M. Friedman, MD won the Best of Cutaneous Applications Abstract Session Award for his paper on the use of a novel optical device to treat vexing nasal telangiectasias. The award was presented at the 2016 Annual Conference of the American S
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Acella Pharmaceuticals Appoints New CEOhttps://practicaldermatology.com/news/acella-pharmaceuticals-appoints-new-ceo/2458613/Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announced the appointment of Harold. A Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and sp
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport